Impact of persistent minimal residual disease post‐consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report
Open Access
- 8 April 2015
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 170 (3) , 367-371
Abstract
Summary: Patient‐specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French‐British‐American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real‐time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD‐positive at EOI and EOC, respectively, with no disease recurrences. MRD after induction and consolidation did not predict relapse and subsequent therapy appeared to eliminate MRD. Thus, assessing MRD at a later time point is warranted in future trials to determine its clinical significance.Keywords
Funding Information
- National Institutes of Health (CA98543)
- National Institutes of Health (CA98413)
- Pediatric Cancer Research Foundation
- National Institutes of Health (U54MD007584)
- St. Baldrick's Foundation
- Thrasher Research Fund
This publication has 10 references indexed in Scilit:
- Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow‐positive Burkitt lymphoma/leukaemia: a Children's Oncology Group ReportBritish Journal of Haematology, 2014
- Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group reportLeukemia, 2012
- Advanced Stage, Increased Lactate Dehydrogenase, and Primary Site, but Not Adolescent Age (≥ 15 Years), Are Associated With an Increased Risk of Treatment Failure in Children and Adolescents With Mature B-Cell Non-Hodgkin's Lymphoma: Results of the FAB LMB 96 StudyJournal of Clinical Oncology, 2012
- Minimal Disseminated Disease in High-Risk Burkitt's Lymphoma Identifies Patients With Different PrognosisJournal of Clinical Oncology, 2011
- Minimal disease assessment in the treatment of children and adolescents with intermediate‐risk (Stage III/IV) B‐cell non‐Hodgkin lymphoma: a children’s oncology group reportBritish Journal of Haematology, 2011
- Screening for Residual Disease in Pediatric Burkitt Lymphoma Using Consensus Primer PoolsAdvances in Hematology, 2009
- Prognostic Role of Minimal Residual Disease in Mature B-Cell Acute Lymphoblastic Leukemia of ChildhoodJournal of Clinical Oncology, 2007
- Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescentsBlood, 2006
- The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95Blood, 2004
- Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults.1980